Releases Geral
Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 5 de fevereiro de 2024
King Faisal Specialist Hospital & Research Centre
RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.
Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasites life cycle within red blood cells. This inhibition significantly disrupts the parasites ability to reproduce, reducing the severity of the diseases symptoms and curbing its spread. This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.
Dr. Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Centre in Jeddah and the lead researcher, stated: “This discovery paves the way for the development of more effective treatments for the deadliest malaria strain, Plasmodium falciparum. Also, this study enhances the scientific communitys understanding of the diseases progression and its interaction with the human immune system, thereby strengthening efforts to combat this widespread malaria parasite prevalent in Africa.
Furthermore, the research demonstrated that the PfAP2-MRP gene regulates the production of genetically diverse protein receptors, allowing the parasite to evade the hosts immune system. This mechanism plays a significant role in the global spread of malaria and underscores the genes importance in developing future therapeutic strategies.
Published in the prestigious journal “Nature” this noteworthy study is part of a close collaboration between KFSH&RC and KAUST to engage in innovative research activities aimed at not only improving the diagnosis of microbes, bacteria, and parasites, but also underscores a global effort to combat pathogens and improve human health.
King Faisal Specialist Hospital and Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.
About King Faisal Specialist Hospital & Research Centre (KFSH&RC):
King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.
In 2023, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.
As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba
CONTACT INFORMATION For more information please contact: Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429 Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Gorilla Technology Group Announces Strategic Partnership with GST Egypt to Provide Networking Capabilities and Manufacturing Facilities in MENA
2 de outubro de 2023Gorilla Technology Group Inc. LONDON, Sept. 28, 2023 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of Smart Country AI, IoT
Saiba Mais -
Releases Geral Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
7 de maio de 2024Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and othe
Saiba Mais -
Releases Geral Última chamada para 4ª Edição do Programa BeFlyers do Futuro
26 de julho de 2024(DINO - 26 jul, 2024) - O BeFlyers do Futuro, uma iniciativa da BeFly que visa criar caminhos além do imaginável para jovens talentos, está de volta para sua
Saiba Mais